<DOC>
	<DOCNO>NCT01411319</DOCNO>
	<brief_summary>The hypothesis study : 1 . Delivery single fraction Lattice Extreme Ablative Dose ( LEAD ) radiotherapy ( RT ) dominant tumor lesion ( ) prostate identify multiparametric functional Magnetic Resonance Imaging safe feasible . 2 . Biomarker expression level differ functional MRI identify suspicious tumor region unsuspicious tumor region . The investigator hypothesize significant source variation biomarker level due tumor heterogeneity molecular abnormality dominant tumor area angiogenic determine outcome .</brief_summary>
	<brief_title>A Phase I Trial MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer</brief_title>
	<detailed_description>The investigator propose use novel method delivery ablative spatially fractionate radiation multiparametric functional MRI define tumor volume framework single-arm phase I clinical trial . The technique , deem Lattice Extreme Ablative Dose ( LEAD ) RT , involve creation high dos shape cylinder DCE-MRI and/or DWI-MRI defined region ( ) adjacent apparently normal prostate lattice framework . The LEAD RT delivery single fraction 12-14 Gy prior standard fraction ( 2.0 Gy per day ) additional 76 Gy ( total dose treatment 88-90 Gy 149 Gy 3.0 2.0 Gy equivalent ) . In protocol investigator also aim examine biomarkers obtain ultrasound-guided prostate biopsy . The patient option refuse pre-RT prostate biopsy plan do patient fiducial marker place . Emphasis place biopsying region multiparametric MRI show enhancement without DWI indicate water restriction . The preferred method protocol research biopsy involve Eigen Artemis® system , allow fusion MRI image ultrasound real time . The Artemis® system FDA approve transrectal ultrasound prostate biopsy device . At present time , Eigen make available u MRI-ultrasound ( MRIus ) fusion software , beta testing . The Eigen Artemis® system fusion software ( FDA approve ) may use fine-tune location tumor biopsy fusion previously obtain multiparametric MRI transrectal ultrasound real time . The ultrasound true guidance image parameter identifies prostate boundary nearby structure . The MRI fuse ultrasound biopsy may direct region ultrasound space . The Eigen Artemis® system software use mean well target tumor region , poorly see ultrasound alone . Recently , Natarajan et al ( 24 ) describe UCLA experience , demonstrate proportion positive biopsy much high use MRIus fusion software , compare ultrasound alone . In protocol , MRIus fusion software may use obtain research biopsy result biopsy ( e.g. , term Gleason score ) use diagnosis ( patient already diagnosis ) influence treatment way . The patient free withdraw protocol time , include upon learn result biopsy . If Eigen Artemis system® unavailable , ultrasound biopsy may perform view functional MRI image separate monitor ultrasound-guided biopsy enhance probability obtain biomarkers representative patient outcome . A third option become available 2012 perform MRI-guided biopsy directly MRI scanner use commercially available approach.. Biomarkers biopsies index lesion ( ) compare tumor area prostate . Biopsy tissue collect pre- post-treatment analyze immunohistochemistry ( IHC ) biomarker quantification .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Biopsy confirm adenocarcinoma prostate . T1T3a disease base digital rectal exam ( DRE ) . T3a disease base MRI acceptable ( evidence frank ( clear cut ) SV involvement invasion bladder rectum ) . Gleason score 610 . Patients Gleason score ≥8 must offer long term androgen deprivation therapy ( ADT ) refuse treatment 46 month ( +/ 2 month ) ( short term ADT ) permit ( require ) protocol . The ADT recommend begin fiducial marker placement ; however , ADT permit start two month prior sign consent . All patient protocol may ( require ) treat 46 month ( +/ 2 month ) ADT , discretion treat physician . Gleason ≥8 must &lt; 40 % tissue involve Gleason 8 biopsy specimen . PSA ≤ 30 ng/mL within 3 month enrollment . If PSA 30 drop ≤30 antibiotic , acceptable enrollment . No previous pelvic radiotherapy . No previous history radical/total prostatectomy ( suprapubic prostatectomy acceptable ) . No concurrent , active malignancy , nonmetastatic skin cancer early stage chronic lymphocytic leukemia ( welldifferentiated small cell lymphocytic lymphoma ) . If prior malignancy remission &gt; 5 year patient eligible . Identifiable multiparametricMRI tumor lesion lesion , total volume &lt; 33 % prostate Multiparametric MRI prostate pelvis require prior protocol consideration . If contrast give , point dose ADC map &lt; 1000 . Ability understand willingness sign write informed consent document . Zubrod performance status &lt; 2 . Willingness fill quality life form . Bone scan negative PSA &gt; 15 ng/mL Gleason ≥ 8 disease . A questionable bone scan acceptable imaging test negative metastasis . Serum testosterone within 40 % normal assay limit ( e.g. , x=0.4*lower assay limit x=.04*upper assay limit + upper assay limit ) , take within 4 month enrollment . Patients start ADT prior sign consent require serum testosterone level prior signing consent ; , serum testosterone prior fiducial marker placement recommend . Serum liver function test ( LFT ) take within 3 month enrollment . Complete blood count take within 3 month enrollment . Age ≥ 35 ≤ 85 year . &gt; T3a disease digital rectal exam &gt; T3a disease clearly identify MRI . Gleason score &lt; 6 . &gt; = 40 % Gleason 810 tumor , total tissue include tumor normal tissue . For example : ( Gleason 810 tumor length/other biopsy tissue length ) *100 = &gt; = 40 % . Androgen deprivation therapy longer 8 month . Androgen deprivation time Luteinizing hormonereleasing hormone ( LHRH ) agonist portion antiandrogen start beforehand purpose counteract surge testosterone LHRH agonist PSA &gt; 30 ng/mL within 3 month enrollment . PSA &gt; 30 ng/mL within 3 month enrollment Unable obtain 1.5T 3.0T multiparametric MRI pelvis prostate contrast . Unidentifiable multiparametric MRI tumor lesion . Identifiable multiparametricMRI tumor lesion , total volume ≥ 33 % prostate . Previous pelvic radiotherapy . Previous history radical prostatectomy . Concurrent , active malignancy , nonmetastatic skin cancer early stage chronic lymphocytic leukemia ( welldifferentiated small cell lymphocytic lymphoma ) . If prior malignancy remission &lt; 5 year patient eligible . Zubrod performance status ≥ 2 . Inability understand unwilling sign write informed consent document Unwilling fill quality life/psychosocial form . Bone scan positive imaging test confirm suspicion metastasis prostate cancer . Serum testosterone within 40 % normal assay limit take within 4 month enrollment ( applicable patient start ADT prior sign consent ) . Serum liver function test ( LFTs ) taen within 3 month enrollment . Complete blood count take within 3 month enrollment . Age &lt; 35 &gt; 85 year .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate Adenocarcinoma</keyword>
</DOC>